ALTERNATIVE APPROACH TO THE TREATMENT OF MODERATE TO SEVERE VAGINAL DRYNESS AND/OR DYSPAREUNIA DUE TO MENOPAUSE1
Osphena® is the first and only SERM indicated for treatment of moderate to severe vaginal dryness and/or dyspareunia due to menopause. All other SERMs have been prescribed for over 50 years to treat additional various women’s health conditions.1,2,3
Unlike estrogens (or products that are metabolized into estradiol), SERMs like Osphena® are hormone free.2
A unique feature of Osphena® is that it demonstrates a strong agonistic effect on vaginal tissue while exhibiting antagonistic or mild agonistic effects on other tissues.4,5
Moreover, Osphena® is the only treatment for moderate to severe vaginal dryness and/or dyspareunia due to menopause, offered conveniently as an oral administration.2
†Premarin® is a registered trademark of Pfizer.
‡Estrace® is a registered trademark of Allergan Pharmaceuticals International Limited.
§Estring® is a registered trademark of Pfizer.
¶Vagifem® is a registered trademark of Novo Nordisk Health Care AG.
**Intrarosa™ is a registered trademark owned by Endoceutics Inc.
††Imvexxy® is a registered trademark of TherapeuticsMD, Inc.
§§Intrarosa™ and Imvexxy® are indicated for the treatment of moderate to severe dyspareunia, a symptom of vulvar and vaginal atrophy, due to menopause.
- Pinkerton JV, Thomas S. Use of SERMs for treatment in postmenopausal women. J Steroid Biochem Mol Biol. 2014;142:142–154.
- Osphena® Prescribing Information. January 2019.
- FDA drug database. Available from: https://www.accessdata.fda.gov/scripts/cder/daf/. Accessed on September 19, 2018.
- Archer DF, Carr BR, Pinkerton JV, et al. Effects of ospemifene on the female reproductive and urinary tracts: translation from preclinical models into clinical evidence. Menopause. 2015;22(7):786–796.
- Wurz GT, Kao CJ, DeGregorio MW. Safety and efficacy of ospemifene for the treatment of dyspareunia associated with vulvar and vaginal atrophy due to menopause. Clin Inter Aging. 2014;9:1939–1950.